- Home
- MRSN vs FNGR Comparison
MRSN vs FNGR Comparison
Compare MRSN & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- FNGR
- Stock Information
- Founded
- MRSN 2001
- FNGR 2016
- Country
- MRSN United States
- FNGR Singapore
- Employees
- MRSN N/A
- FNGR N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- MRSN Health Care
- FNGR Technology
- Exchange
- MRSN Nasdaq
- FNGR Nasdaq
- Market Cap
- MRSN 71.9M
- FNGR 72.0M
- IPO Year
- MRSN 2017
- FNGR N/A
- Fundamental
- Price
- MRSN $0.34
- FNGR $1.37
- Analyst Decision
- MRSN Buy
- FNGR
- Analyst Count
- MRSN 3
- FNGR 0
- Target Price
- MRSN $4.00
- FNGR N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- FNGR 284.4K
- Earning Date
- MRSN 03-03-2025
- FNGR 01-14-2025
- Dividend Yield
- MRSN N/A
- FNGR N/A
- EPS Growth
- MRSN N/A
- FNGR N/A
- EPS
- MRSN N/A
- FNGR N/A
- Revenue
- MRSN $40,497,000.00
- FNGR $33,570,107.00
- Revenue This Year
- MRSN N/A
- FNGR $260.03
- Revenue Next Year
- MRSN N/A
- FNGR N/A
- P/E Ratio
- MRSN N/A
- FNGR N/A
- Revenue Growth
- MRSN 9.88
- FNGR N/A
- 52 Week Low
- MRSN $0.34
- FNGR $1.03
- 52 Week High
- MRSN $4.64
- FNGR $3.96
- Technical
- Relative Strength Index (RSI)
- MRSN 29.11
- FNGR 47.83
- Support Level
- MRSN $0.41
- FNGR $1.55
- Resistance Level
- MRSN $0.42
- FNGR $1.83
- Average True Range (ATR)
- MRSN 0.04
- FNGR 0.14
- MACD
- MRSN -0.00
- FNGR -0.00
- Stochastic Oscillator
- MRSN 3.43
- FNGR 20.69
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.